Literature DB >> 19114694

Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database.

Deborah T Blumenthal1, Minhee Won, Minesh P Mehta, Walter J Curran, Luis Souhami, Jeff M Michalski, C Leland Rogers, Benjamin W Corn.   

Abstract

PURPOSE: To analyze the Radiation Therapy Oncology Group (RTOG) database of patients with glioblastoma and appraise whether outcome was influenced by time to initiation of radiation therapy (RT). PATIENTS AND METHODS: From 1974 through 2003, adult patients with histologically confirmed supratentorial glioblastoma were enrolled onto 16 RTOG studies. Of 3,052 enrolled patients, 197 patients (6%) were either initially rendered ineligible or had insufficient chronologic data, leaving a cohort of 2,855 patients for the present analysis. We selected four patient groups based on the interval from surgery to the start of RT: <or= 2 weeks, 2 to 3 weeks, 3 to 4 weeks, more than 4 weeks to the protocol eligibility limit of 6 weeks. Survival times were estimated by the Kaplan-Meier method. Multivariate analysis incorporated variables of time interval, recursive partitioning analysis (RPA) class, and treatment regimen.
RESULTS: No decrement in survival could be identified with increasing time to initiation of RT. Among our four temporal groupings, median survival time was unexpectedly and significantly greater in the group with the longest interval (> 4 weeks) than in those with the shortest delay (<or= 2 weeks): respectively, 12.5 months versus 9.2 months (P < .0001). On multivariate analysis, with overall survival as the end point, time interval more than 4 weeks and lower RPA class were both significant predictors of improved outcome. Treatment regimen was not a significant factor.
CONCLUSION: There is no evident reduction in survival by delaying initiation of RT within the relatively narrow constraint of 6 weeks. An unanticipated yet significantly superior outcome was identified for patients for whom RT was delayed beyond 4 weeks from surgery.

Entities:  

Mesh:

Year:  2008        PMID: 19114694      PMCID: PMC2645087          DOI: 10.1200/JCO.2008.18.9035

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  39 in total

1.  A synopsis of radiation oncology in Australia, with particular reference to New South Wales.

Authors:  G W Morgan
Journal:  Aust N Z J Surg       Date:  1998-03

2.  Effect of time interval between breast-conserving surgery and radiation therapy on ipsilateral breast recurrence.

Authors:  P J Froud; D Mates; J S Jackson; N Phillips; S Andersen; S M Jackson; C J Bryce; I A Olivotto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

3.  Radiotherapy with and without chemotherapy after breast conservation surgery for early stage breast cancer: a review of timing.

Authors:  F L Ampil; G V Burton; B D Li; G M Mills
Journal:  Eur J Gynaecol Oncol       Date:  1999       Impact factor: 0.196

4.  Irradiation after surgically induced brain injury in the rat: timing in relation to severity of radiation damage.

Authors:  Selcuk Peker; Ufuk Abacioglu; Ibrahim Sun; Meral Yuksel; M Necmettin Pamir
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

5.  Does delay in breast irradiation following conservative breast surgery in node-negative breast cancer patients have an impact on risk of recurrence?

Authors:  O Vujovic; F Perera; A R Dar; L Stitt; E Yu; S M Voruganti; P T Truong
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-03-01       Impact factor: 7.038

6.  The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy.

Authors:  C S Tsai; C H Lai; C C Wang; J T Chang; T C Chang; C J Tseng; J H Hong
Journal:  Gynecol Oncol       Date:  1999-12       Impact factor: 5.482

7.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme.

Authors:  J Del Rowe; C Scott; M Werner-Wasik; J P Bahary; W J Curran; R C Urtasun; B Fisher
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

9.  Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

Authors:  Olivier L Chinot; Maryline Barrié; Stephane Fuentes; Nathalie Eudes; Sophie Lancelot; Philippe Metellus; Xavier Muracciole; Diane Braguer; L'Houcine Ouafik; Pierre-Marie Martin; Henry Dufour; Dominique Figarella-Branger
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

10.  Radiotherapy for glioblastoma in the elderly.

Authors:  Florence Keime-Guibert; Olivier Chinot; Luc Taillandier; Stéphanie Cartalat-Carel; Marc Frenay; Guy Kantor; Jean-Sébastien Guillamo; Eric Jadaud; Philippe Colin; Pierre-Yves Bondiau; Philippe Meneï; Hugues Loiseau; Valérie Bernier; Jérôme Honnorat; Maryline Barrié; Karima Mokhtari; Jean-Jacques Mazeron; Anne Bissery; Jean-Yves Delattre
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

View more
  41 in total

1.  Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.

Authors:  Georges Noel; Aymeri Huchet; Loic Feuvret; Jean Philippe Maire; Pierre Verrelle; Emilie Le Rhun; Maud Aumont; François Thillays; Marie Pierre Sunyach; Chantal Henzen; Fernand Missohou; Renaud de Crevoisier; Pierre Yves Bondiau; Philippe Collin; Xavier Durando; Gilles Truc; Christine Kerr; Valérie Bernier; Jean-Baptiste Clavier; David Atlani; Anne D'Hombres; Sandrine Vinchon-Petit; Jean Léon Lagrange; Luc Taillandier
Journal:  J Neurooncol       Date:  2012-06-02       Impact factor: 4.130

Review 2.  Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line?

Authors:  Yaacov Richard Lawrence; Deborah T Blumenthal; Diana Matceyevsky; Andrew A Kanner; Felix Bokstein; Benjamin W Corn
Journal:  J Neurooncol       Date:  2011-04-24       Impact factor: 4.130

3.  NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.

Authors:  Arif N Ali; Peixin Zhang; W K Alfred Yung; Yuhchyau Chen; Benjamin Movsas; Raul C Urtasun; Christopher U Jones; Kwang N Choi; Jeff M Michalski; A Jennifer Fischbach; Arnold M Markoe; Christopher J Schultz; Marta Penas-Prado; Madhur K Garg; Alan C Hartford; Harold E Kim; Minhee Won; Walter J Curran
Journal:  J Neurooncol       Date:  2018-02-05       Impact factor: 4.130

4.  Survival impact of postoperative radiotherapy timing in pediatric and adolescent medulloblastoma.

Authors:  Alexander L Chin; Everett J Moding; Sarah S Donaldson; Iris C Gibbs; Scott G Soltys; Susan M Hiniker; Erqi L Pollom
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

5.  Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.

Authors:  Haihui Jiang; Wei Zeng; Xiaohui Ren; Yong Cui; Mingxiao Li; Kaiyuan Yang; Mohammad Elbaroody; Song Lin
Journal:  J Neurooncol       Date:  2019-06-07       Impact factor: 4.130

6.  [Prediction of clinical course of glioblastomas by MRI during radiotherapy].

Authors:  Christina Leitzen; Hans H Schild; Birgitta Bungart; Ulrich Herrlinger; Christiana Lütter; Thomas Müdder; Timo Wilhelm-Buchstab; Heinrich Schüller
Journal:  Strahlenther Onkol       Date:  2010-11-29       Impact factor: 3.621

7.  Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.

Authors:  Jay K Nathan; Amanda L Brezzell; Michelle M Kim; Denise Leung; D Andrew Wilkinson; Shawn L Hervey-Jumper
Journal:  J Neurooncol       Date:  2017-07-25       Impact factor: 4.130

8.  Impact of radiotherapy delay on survival in glioblastoma.

Authors:  Izaskun Valduvieco; Eugènia Verger; Jordi Bruna; Lluís Caral; Teresa Pujol; Teresa Ribalta; Teresa Boget; Laura Oleaga; Estela Pineda; Francesc Graus
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

9.  Potential clinical predictors of outcome after postoperative radiotherapy of non-small cell lung cancer.

Authors:  R Bütof; K Kirchner; S Appold; S Löck; A Rolle; G Höffken; M Krause; M Baumann
Journal:  Strahlenther Onkol       Date:  2014-01-12       Impact factor: 3.621

10.  Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice.

Authors:  J A B van Genugten; P Leffers; B G Baumert; H Tjon-A-Fat; A Twijnstra
Journal:  J Neurooncol       Date:  2009-07-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.